Teleflex Incorporated, headquartered in Wayne, Pennsylvania, is an American provider of specialty medical devices for a range of procedures in critical care and surgery.
| Revenue (TTM) | $2.25B |
| Gross Profit (TTM) | $1.24B |
| EBITDA | $403.90M |
| Operating Margin | 14.40% |
| Return on Equity | -0.70% |
| Return on Assets | 1.75% |
| Revenue/Share (TTM) | $51.16 |
| Book Value | $68.55 |
| Price-to-Book | 2.00 |
| Price-to-Sales (TTM) | 2.50 |
| EV/Revenue | 3.719 |
| EV/EBITDA | 32.77 |
| Quarterly Earnings Growth (YoY) | -17.30% |
| Quarterly Revenue Growth (YoY) | 28.90% |
| Shares Outstanding | $42.37M |
| Float | $42.21M |
| % Insiders | 0.49% |
| % Institutions | 114.63% |
Volatility is currently contracting
Investors interested in Medical - Instruments stocks are likely familiar with Teleflex (TFX) and Penumbra (PEN). But which of these two stocks presents investors with the better value opportunity right now?
Evaluate Teleflex's (TFX) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Teleflex Incorporated (TFX) Q2 2026 Earnings Call Transcript
While the top- and bottom-line numbers for Teleflex (TFX) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Teleflex (TFX) came out with quarterly earnings of $1.76 per share, beating the Zacks Consensus Estimate of $1.28 per share. This compares to earnings of $3.73 per share a year ago.
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable September 30, 2026, to shareholders of record at the close of business on August 14, 2026. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to bec.
Combining leading in-house expertise with platform-enhancing investments to accelerate advances in engineering, innovation and manufacturing capabilities serving global medical device innovators Marks completion of acquisition by Montagu and Kohlberg PLYMOUTH, Minn., Aug. 04, 2026 (GLOBE NEWSWIRE) -- INGENYX, formerly Teleflex Medical OEM, today announced its launch as an independent company following the completion of its acquisition by Montagu and Kohlberg and carve-out from Teleflex Incorporated (NYSE: TFX).
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, August 6, 2026. To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company's website, teleflex.com. An audio replay of the call will be available beginning.
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) has been awarded a national group purchasing agreement for central venous access products with Premier, Inc. Effective July 1, 2026, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for select Teleflex products, including short-term central venous catheters, arterial catheter products, and intraosseous vascular access solutions. “As healthcare sys.
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has published its 2025 Global Impact Report. The report outlines recent accomplishments and future plans to support the Company's Corporate Social Responsibility (CSR) program. The report aligns with the Global Reporting Initiative (GRI), the Sustainability Accounting Standards Board (SASB), and Taskforce on Climate-Related Financial Disclosures (TCFD). “This yea.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on TFX and any ticker you trade — then tracks every position and per-strategy win rate.
